TriSalus Life (TLSI) news

Recent news

Trisalus Life Sciences Q2 EPS USD -0.16

Trisalus Life Sciences, Inc. (Nasdaq: TLSI) reported a net loss per share of -$0.16 for the second quarter of 2026, based on its most recent financial disclosures. This figure reflects the company’s continued investment in research and development, as well as its strategic expansion of TriNav® and…

AInvest Wire · Aug 6, 2026

Trisalus Life Sciences - maintains FY2026 revenue guidance of $54 mln-$57 mln

AInvest Wire · Aug 6, 2026

TriSalus Life Sciences Q4 2023 GAAP EPS $(1.56) Misses $(0.69) Estimate, Sales $5.721M Beat $5.453M Estimate

AInvest Wire · Apr 1, 2024

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by